CERo Therapeutics Soars 15.17% on FDA Orphan Drug Designation

On June 17, 2025, CERo Therapeutics surged 15.17% in pre-market trading, marking a significant rise in its stock price.

CERo Therapeutics received a notable boost from the FDA, which granted orphan drug designation to one of its treatments aimed at acute myeloid leukemia. This designation is a crucial milestone for the company, as it advances its efforts to develop effective therapies for this aggressive form of blood cancer.

Analysts have also shown optimism towards CERo Therapeutics, with an average price target of $60.00, suggesting a potential upside of 773.62% from its current price. This bullish outlook is further supported by a consensus recommendation of "Outperform" from brokerage firms, indicating a strong belief in the company's future performance.